Zephyr AI Appoints Allen Hodge as Chief Commercial Officer

Published on : Published by : BioBuzz Media

Zephyr AI, Inc. (“Zephyr AI”), a high-growth healthcare technology company committed to radically reshaping traditional approaches to drug discovery precision medicine and predictive analytics has announced the appointment of Allen Hodge as Chief Commercial Officer. Hodge brings more than two decades of experience in building commercial organizations to this role. Prior to joining Zephyr AI, Hodge served as Senior Vice President and U.S. General Manager at BioCryst Pharmaceuticals, delivering a successful launch of Orladeyo for patients with hereditary angioedema.

Red Cell Forms Zephyr AI to Revolutionize Drug Discovery and Precision Medicine

Zephyr AI Logo
Published on : Published by : BioBuzz Media

Zephyr AI’s mission is to transform drug discovery, redefine personalized medicine, and empower healthcare systems to achieve better patient outcomes at lower cost. Zephyr AI integrates artificial intelligence with extensive datasets to upend traditional “guess and test” drug development and personalized medicine processes to unearth novel therapeutics, new applications for existing therapeutics, and advanced biomarkers for individualized treatments.